A landmark randomized trial demonstrates striking improvements in chemotherapy response when vitamin D3 supplementation is incorporated into treatment protocols. Women receiving 2,000 IU/day of vitamin D3 during neoadjuvant chemotherapy achieved a pathological complete response rate of 43%, compared to just 24% in the placebo group—representing a 79% relative increase in treatment efficacy.
This 19-percentage-point absolute difference carries significant clinical implications. The trial enrolled 80 postmenopausal women with breast cancer over a 6-month treatment period, with 75 completing the full protocol. These findings suggest that baseline vitamin D status may be a measurable predictor of chemotherapy responsiveness, particularly given the widespread deficiency observed at enrollment. Such data-driven insights support consideration of vitamin D assessment and supplementation in individualized cancer treatment strategies.
Read the full article on GMJ Newsroom.
Was this article helpful?
